Advertisement
NVS vs SNY
NVS vs SNY Stock Comparison: Momentum Clash in Pharma
Key Takeaways
- NVS has surged over 50% in the past year, hitting new 52-week highs around $163, driven by strong pipeline data.
- SNY trades near $46, down about 13% annually amid CEO transition and pipeline concerns, offering higher dividend yield near 4.8%.
- NVS boasts larger market cap (~$310B vs ~$111B for SNY) and recent positive Phase III results for kidney drug Vanrafia.
- Both deliver solid dividends (NVS ~2.9%), but SNY shows stronger Q4 EPS beat while NVS gains on momentum.
- AI models favor NVS for trend consistency and scale in recent market activity.
Introduction
Novartis AG (NVS) and Sanofi SA (SNY) stand as European pharmaceutical giants with global footprints in innovative medicines, vaccines, and specialty care. This NVS vs SNY stock comparison examines their relative performance amid shifting sector dynamics, including pipeline advancements and leadership changes. Traders seeking momentum plays may eye NVS's upward trajectory, while income-focused investors could favor SNY's yield. Understanding their business models, recent market positioning, and head-to-head metrics aids in navigating healthcare sector volatility for informed relative performance decisions.
NVS Overview and Recent Performance
Novartis AG (NVS), headquartered in Basel, Switzerland, focuses on innovative pharmaceuticals across oncology, immunology, cardiovascular, and renal therapies. With a market cap exceeding $310 billion, NVS generates trailing revenue around $56 billion. In recent market activity, the stock has shown robust momentum, climbing over 13% in the past month and 55% over the last year to reach 52-week highs near $163. Key drivers include promising Phase III data for Vanrafia in IgA nephropathy, bolstering its renal portfolio, alongside plans for a new U.S. radioligand therapy facility. Despite mixed Q4 results with revenue slightly below expectations, analysts view NVS as undervalued with a forward P/E around 17.6 and a 2.9% dividend yield, fueling positive sentiment.
SNY Overview and Recent Performance
Sanofi SA (SNY), based in Paris, France, specializes in immunology, vaccines, rare diseases, and oncology, with trailing revenue near $55 billion and a market cap of about $111 billion. Recent weeks have pressured SNY, with shares dipping around 2% to $46 amid a sudden CEO transition from Paul Hudson to Belén Garijo, raising questions on strategic continuity. The stock lags yearly, down over 12%, contrasting its Q4 EPS beat of $0.89 versus estimates. Acquisitions like Dynavax for hepatitis B vaccines and positive data on Beyfortus for RSV provide offsets, supporting a trailing P/E near 19 and attractive 4.8% dividend yield that appeals to yield seekers despite softer momentum.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers using advanced Financial Learning Models. Only the most suitable for prevailing market conditions—factoring volatility levels like low, medium, or high—earn a spot, with over 40 showcased across sectors such as semiconductors, aerospace, and ETFs. These bots deliver standout stats: annualized returns from +15% to over +300%, win rates of 55-95%, and profit factors up to 34. Examples include a 5-minute MPWR semiconductor bot at +98% annualized with 70% win rate, and a 60-minute AeroDefense DFEN agent at +121% with 74% win rate. Spanning styles from scalping to swing trading on 5-60 minute timeframes, they adapt via back-tested, forward-tested results. Traders can explore these high-potential tools to complement strategies in stocks like NVS and SNY.
Head-to-Head Comparison
NVS and SNY share European roots and diversified pharma exposure but diverge in scale and momentum. NVS's larger $310B market cap dwarfs SNY's $111B, reflecting stronger growth perception with 2% quarterly revenue gains versus SNY's steadier vaccine-driven topline. Recent momentum favors NVS's 55% yearly rise on pipeline catalysts like Vanrafia, while SNY trails at -13% amid leadership flux, heightening risk factors. Both offer sector resilience in immunology and oncology, but NVS edges in stability (beta 0.46 vs 0.37) and trend consistency; SNY counters with higher yield (4.8% vs 2.9%) for income trade-offs. Market sentiment tilts toward NVS's undervaluation, though SNY's acquisitions signal pipeline potential.
Tickeron AI Verdict
Tickeron’s AI models currently favor NVS over SNY, citing superior trend consistency, pipeline momentum from recent renal data, larger scale, and relative stability in volatile markets. Probabilistic analysis highlights NVS's stronger mid-term positioning for outperformance, though SNY appeals probabilistically for yield in consolidation scenarios.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a StrongBuy and SNY is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVS’s FA Score shows that 3 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).
- NVS’s FA Score: 3 green, 2 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVS’s TA Score shows that 3 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).
- NVS’s TA Score: 3 bullish, 5 bearish.
- SNY’s TA Score: 4 bullish, 5 bearish.
Price Growth
NVS (@Pharmaceuticals: Major) experienced а +1.82% price change this week, while SNY (@Pharmaceuticals: Major) price change was -2.13% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.63%. For the same industry, the average monthly price growth was -7.17%, and the average quarterly price growth was +8.03%.
Reported Earning Dates
NVS is expected to report earnings on Apr 28, 2026.
SNY is expected to report earnings on Apr 23, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.63% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| NVS | SNY | NVS / SNY | |
| Capitalization | 295B | 107B | 276% |
| EBITDA | 22.8B | 12.5B | 182% |
| Gain YTD | 18.255 | -10.029 | -182% |
| P/E Ratio | 21.46 | 18.75 | 114% |
| Revenue | 56.7B | 46.7B | 121% |
| Total Cash | 2.58B | 8.47B | 30% |
| Total Debt | 35.4B | 20.3B | 174% |
NVS | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 6 | 80 | |
SMR RATING 1..100 | 30 | 67 | |
PRICE GROWTH RATING 1..100 | 41 | 77 | |
P/E GROWTH RATING 1..100 | 37 | 80 | |
SEASONALITY SCORE 1..100 | 65 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (9) in the Pharmaceuticals Major industry is in the same range as NVS (16). This means that SNY’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for SNY (80). This means that NVS’s stock grew significantly faster than SNY’s over the last 12 months.
NVS's SMR Rating (30) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (67). This means that NVS’s stock grew somewhat faster than SNY’s over the last 12 months.
NVS's Price Growth Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (77). This means that NVS’s stock grew somewhat faster than SNY’s over the last 12 months.
NVS's P/E Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (80). This means that NVS’s stock grew somewhat faster than SNY’s over the last 12 months.
| NVS | SNY | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 43% | 4 days ago 63% |
| Stochastic ODDS (%) | 4 days ago 40% | 4 days ago 49% |
| Momentum ODDS (%) | 4 days ago 39% | 4 days ago 46% |
| MACD ODDS (%) | 4 days ago 43% | 4 days ago 50% |
| TrendWeek ODDS (%) | 4 days ago 52% | 4 days ago 49% |
| TrendMonth ODDS (%) | 4 days ago 49% | 4 days ago 45% |
| Advances ODDS (%) | 21 days ago 50% | 18 days ago 52% |
| Declines ODDS (%) | 4 days ago 42% | 4 days ago 48% |
| BollingerBands ODDS (%) | 4 days ago 61% | 4 days ago 54% |
| Aroon ODDS (%) | 4 days ago 46% | 4 days ago 51% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MULL | 175.65 | 16.21 | +10.17% |
| GraniteShares 2x Long MU Daily ETF | |||
| RSPN | 58.47 | -0.11 | -0.19% |
| Invesco S&P 500® Equal Wt Indls ETF | |||
| VIG | 217.54 | -0.55 | -0.25% |
| Vanguard Dividend Appreciation ETF | |||
| POWA | 87.59 | -0.40 | -0.46% |
| Invesco Bloomberg Pricing Power ETF | |||
| XNAV | 82.28 | -0.70 | -0.84% |
| FundX Aggressive ETF | |||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with SNYNF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then SNYNF could also see price increases.